CURRICULUM VITAE (CV ) Institutul Oncologic Al.Trestiorean u Bucuresti. Sept sept Specialist oncologie medicala

Transcription

1 CURRICULUM VITAE (CV ) 1. Nume: VOLOVAT 2. Prenume: CONSTANTIN 3. Data şi locul naşterii: 22 apr 1959, ROMAN, JUD.NEAMT 4. Cetăţenie: ROMANA 5. Stare civilă: CASATORIT 6. Studii: Instituţia Perioada: de la (luna, anul) până la (luna, anul) Grade sau diplome obţinute Univ. de Medicina si Farmacie GR.T.POPA IASI Sept.1979 Sept DOCTOR - MEDIC Institutul Oncologic Al.Trestiorean u Bucuresti Sept sept.1993 Specialist oncologie medicala Institutul Oncologic Al.Trestioreanu Bucuresti Univ. AL.I.CUZA IASI 1997 Mai mai 2004 Medic primar oncologie medicala 7. Titlul ştiinţific: doctorand UMF GR.T.POPA Indrumator Prof.dr. E.Zbranca 8. Experienţa profesională: Perioada: de la..(luna, anul) până la..(luna, anul) Sept dec Ian pana in prezent Locul: Policlinica judeteana Policlinica judeteana Instituţia: Funcţia: Descriere: Spitalul Univ. Sf.Spiridon Iasi Medic coordonator oncologie ambulatoriu jud. Iasi Profilaxie, diagnostic, tratament sistemic si dispensarizare in cancer Centrul de Oncologie Medicala Medic coordonator Profilaxie, diagnostic, tratament sistemic si dispensarizare in cancer Master in Servicii de Sanatate Publica 9. Locul de muncă actual şi funcţia: medic coordonator - Centrul de Oncologie Medicala SCM 10. Vechime la locul de muncă actual: 8 ANI 11. Brevete de invenţii: 12. Lucrări elaborate şi / sau publicate (se prezinta lista cuprinzand maxim 5 (cinci) lucrari in domeniul proiectului, relevante pentru activitatile ce urmeaza a fi desfasurate in cadrul proiectului): 13. Membru al asociaţiilor profesionale: - din 1997 membru fondator al Societatii Romane de Oncologie Medicala - din 2001 membru al American Society of Clinical Oncology (ASCO) 14. Limbi straine cunoscute: ENGLEZA, FRANCEZA 15. Specializări şi calificări: - februarie training - Royal Marsden Hospital, London Glioma Perceptorship Program - mai 1999 training - European School of Oncology, Vienna Training in clinical trials martie 2007 training Buna Practica in Studiul Clinic curs pentru investigatori si monitori Verumedu SRL

2 16. Experienţa acumulată (inclusiv experienta manageriala) în programe/proiecte naţionale/internaţionale: Programul/Proiectul Funcţia Perioada: de la... până la... Comisia Nationala de Oncologie Ministerul Sanatatii membru al Sub-comisiei de 1998 Statistica, Organizare si Baze de Date Ministerul Sanatatii consultant august mai Alte competenţe: 18. Alte menţiuni: Experienta ca Investigator Principal (P.I.) in Studii Clinice cu beneficiu terapeutic (de faza II- III) multicentrice, multinationale (aprobate de Agentia Nationala a Medicamentului si Comisia Nationala de Etica si desfasurate sub supravegherea FDA si EMEA) : 1). In colaborare cu OCC ( Compania de Cercetare Clinica) PAREXEL International Romania s.r.l phase II/III study - A double blind, randomized, parallel group, placebo controlled, comparative study of efficacy, safety and tolerability of cannabis based medicine extracts (CBME) in patients with cancer-related pain Protocol GWCA perioada - ianuarie 2003 martie pacienti randomizati 2.- phase II/III study Symptomatic malignant ascites using paracentesis plus the tri-functional antibody, - perioada octombrie.2004-noiembrie.2005, 4 pacienti randomizati; 3. phase II/III study Efficacy and safety of XM21 compared with filgrastim in patients with non-small cell lung cancer receiving chemotherapy with platinum compounds - perioada - decembrie 2004 mai 2005, 19 pacienti randomizati 4 - Phase II Study Comparing 5FU/FA Plus Oxaliplatin Plus Cetuximab vs 5-FU/FA Plus Oxaliplatin as First-Line Treatment for EGFR-Expressing Metastatic Colorectal Cancer - perioada - februarie.2006 mai 2006, 8 patienti randomizati; 5. - Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab vs. 5FU/FA Plus Irinotecan as First-Line Treatment for EGFR-Expressing Metastatic Colorectal Cancer - perioada august 2005 decembrie 2005, 9 patienti randomizati; 6.- Phase II Study Efficacy and safety of XM01 compared to placebo and Epoetin beta in patients with solid tumours receiving platinum containing chemotherapy - perioada - ianuarie 2006 august 2006, 25 pacienti randomizati 7.- Phase II Study - Efficacy and safety of XM01 compared to placebo and Epoetin beta in patients with solid tumours receiving non-platinum containing chemotherapy - perioada - ianuarie 2006 mai pacienti randomizati 2). In colaborare cu OCC ( Compania de Cercetare Clinica) WYETH International 1. - A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study of Oral CCI-779 (temsirolimus) Administered in Combination with Letrozole vs. Letrozole Alone as First Line Hormonal Therapy in Postmenopausal Women with Locally Advanced or Metastatic Breast Cancer - Protocol Number 3066A1-303WW 2

3 - perioada ianuarie decembrie 2005, 12 pacienti randomizati 3). In colaborare cu OCC ( Compania de Cercetare Clinica) M&M Clinical Research Enterprise Ltd phase III study Symptomatic malignant ascites using paracentesis plus the tri-functional antibody - perioada octombie 2005-prezent, 9 patienti randomizati; 2. - A Phase III Clinical Study of treatment with Thym-Uvocal vs. Placebo in Metastatic Colorectal Carcinoma - perioada - octombrie 2005 februarie 2006, 7 pacienti randomizati 4). In colaborare cu OCC ( Compania de Cercetare Clinica) PSI PHARMA SUPPORT 1.- A Multicenter Phase 3, Randomized Comparison of the Safety and Efficacy of Weekly TOCOSOL(R) Paclitaxel vs. Weekly Paclitaxel Injection in the Treatment of Metastatic Breast Cancer - perioada - ian 2006 august 2006, 8 patienti randomizati; 2. Studiu de fază III, randomizat, controlat, asupra medicamentului picoplatin şi cea mai bună îngrijire medicală faţă de exclusiv cea mai bună îngrijire medicală la pacienţi cu cancer pulmonar cu celule mici, refractar sau progresiv în termen de şase luni de la încetarea chimioterapiei de prima linie pe bază de platină - debut apr pacienti randomizati 3. Protocolul KTN32313R Studiu de fază 3 asupra siguranţei şi eficacităţii tratamentului cu karenitecin faţă de topotecan administrate timp de 5 zile consecutiv o dată la 3 săptămâni pacientelor cu cancer ovarian epitelial în stadiu avansat - debut - dec ). In colaborare cu OCC ( Compania de Cercetare Clinica) JOHNSON & JOHNSON 1. - A Randomized Controlled Study of Docetaxel Monotherapy or DOXIL /CAELYX and Docetaxel for the Treatment of Advanced Breast Cancer - perioada - ianuarie.2006 sept.2006, 10 patienti randomizati; 2. - Phase III A Randomized, Open-Label, Multicenter Study Evaluating Thrombovascular Events in Subjects with Cancer Receiving Chemotherapy and Administered Epoetin Alfa Once or Three Times a Week for the Treatment of Anemia - perioada martie 2007 prezent, 4 pacienti randomizati 6). In colaborare cu OCC ( Compania de Cercetare Clinica) PRA INTERNATIONAL 3

4 1. - A Phse II Study for immunological evaluation, efficacy adn safety of treatment with HER 2 AUTO VAC Protein + STIMULON ADJUVANT QS-21 in monotherapy at pacients with metastatic breast cancer - Protocol PX perioada ian 2005 mai 2005, 2 paciente randomizate 2. - A Phase III Open Label, Randomized Two-Parallel-Arm Multicenter Study of E7389 vs Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes and Refractory to the Most Recent Chemotherapy - perioada - ianuarie prezent, 8 patienti randomizati; 3. - Phase II Once Per Cycle Treatment of Anemia With Darbepoetin Alfa With Iron in Subjects With Non Myeloid Malignancies - perioada - aprilie 2007 prezent, 11 patienti randomizati 4. - Phase III clinical study, START (Stimulating Targeted Antigenic Responses To NSCLC), assessing the efficacy and safety of Stimuvax (BLP25 liposome vaccine) as a potential treatment for patients with unresectable stage III non-small cell lung cancer (NSCLC) - debut - iunie pacient randomizat 7). In colaborare cu OCC ( Compania de Cercetare Clinica) GLAXO SMITHKLINE 1. - Phase III Multicenter, Randomized, Double-Blind, Chemo-therapy-Induced Nausea and Vomiting in Cancer Subjects - perioada ianuarie 2007 prezent, 20 patienti randomizati; 2. - A Randomised Study, Open Label, multicentric, phase III, for comparing the activity of Lapatinib monotherapy, Trastuzumab monotherapy, sequential therapy with Trastuzumab followed by Lapatinib and concomitant treatment with Lapatinib and Trastuzumab, as adjuvant treatment in patients with breast cancer with hiperexpression of Erb B2 and/or Erb B2 amplification - Studiul Clinic EGF ALTTO - debut - iunie paciente randomizate 8). In colaborare cu OCC ( Compania de Cercetare Clinica) PHARMANET ROMANIA 1.- Open-Label Expanded Access Study of Lapatinib and Capecitabine Therapy in Subjects with Breast Cancer - perioada mai 2007 pana in prezent, 1 pacienta randomizata 2. CT 4002 An open-label, randomized, controlled Phase-II trial evaluating the efficacy and safety of EndoTAG-1 in triple receptor negative breast cancer patients - debut ian ). In colaborare cu OCC ( Compania de Cercetare Clinica) COVANCE ROMANIA 1.- A Phase III, multicenter,placebo-controlled, double blind, randomised clinical trial to evaluate the efficacy of Bevacizumab in combination with Tarceva compared with Tarceva alone 4

5 for treatment of Advanced No-Small Cell Lung Cancer, after Failure of Standard first line chemotherapy (Studiul ATLAS si Studiul BETA) - debut iunie pacienti randomizati 2. A phase II Biomarker Identification Trial for Erlotinib (Tarceva ) in Patients with Advanced Pancreatic Carcinoma. - debut feb ). In colaborare cu OCC SANOFI-AVENTIS A Multinational, Randomized, Double-blind Study Comparing the Efficacy of Aflibercept Once every 2 weeks versus Placebo in Patients Treated with Gemcitabine for Metastatic Pancreatic Cancer Patient (MPC) (VANILLA ) -debut feb ). In colaborare cu OCC ( Compania de Cercetare Clinica) KENDLE ROMANIA 1. A Pivotal Trial to Determine the Efficacy and Safety of AP23573 when Administered as Maintenance Therapy to Patients with Metastatic Soft-Tissue or Bone Sarcomas - debut ian ). In colaborare cu OCC ( Compania de Cercetare Clinica) CLINICAL TRIALS COMPANY 1. Protocol GCF071 Titlu: Studiu faza III randomiz.,multicentric,dublu-orb,de echivalenta terapeutica intre G- CSF(Pliva/Mayne Filgrastim ) versus Neupogen (filgrastim Amgen) la subiecti aflati in tratament cu docetaxel-doxorubicin pentru cancer de san - Debut octombrie paciente randomizate 13). In colaborare cu OCC ( Compania de Cercetare Clinica) KOSAN BIOSCIENCE 1. Phase 2 Clinical Trial of Intravenous Alvespimycin (KOS-1022) in Patients with Her2 Positive Breast Cancer - debut - dec ). In colaborare cu OCC ( Compania de Cercetare Clinica) - i3 1. A Multicentre, Open-Label, Extension Study to Investigate the Safety and Efficacy of AD 923 (Fentanyl Sublingual) for the Treatment of Breakthrough Cancer Pain in Subjects with Malignancies - debut dec ). In colaborare cu OCC ( Compania de Cercetare Clinica) INC RESEARCH 1. An Open-label, Sequential, Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Dose Response of Fixed, Repeated Doses of NE-180 (GlycoPEGylated rhuepo) in Anemic Cancer Patients Receiving Chemotherapy Protocol No.: NE debut dec pacienti randomizati 5

6 PUBLICATII CORELATE CU PROIECTUL 1. International Classification of Diseases for Oncology ICD-O World Health Organisation 2000, membru in colectivul de traducere in limba romana Alte lucrari in curs de prezentare (ASCO 2008) la adresele : 022CE8C%2DA769%2D4C00%2DBC07%2D E8E2%7D&Ckey=%7BD4CF6F59%2DCAEE%2D4B55%2D A27D%2D39BA767F0867%7D 022CE8C%2DA769%2D4C00%2DBC07%2D E8E2%7D&Ckey=%7BC255444C%2D771B%2D4D0D%2D A740%2DED41C9C1FD90%7D 6